Tag: capital

FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced the pricing of an underwritten public offering for gross proceeds of approximately $6 million prior to deducting underwriting commissions and offering expenses.

SARASOTA, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced that it has entered into a placement agency agreement for the purchase and sale of up to 800,000 shares of the Company’s Series H Convertible Preferred Stock (“Preferred Stock”), no par value, and Warrants to purchase up to an additional 800,000 shares of Preferred Stock of the Company at an exercise price of $25.00 per share (the “Warrants”). The combined public Offering price of each share of Preferred Stock together with an accompanying Warrant is $25.00 (the “Offering”). The Preferred Stock is convertible into the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a conversion price of $2.50 per share. The closing of the Offering is expected to occur on or about July 2, 2025, subject to the satisfaction of customary closing conditions.

LAS VEGAS, July 01, 2025 (GLOBE NEWSWIRE) -- via IBN -- Golden Triangle Ventures, Inc. (OTC PINK: GTVH) ("GTV" or the "Company") is pleased to announce the completion of a significant restructuring of its legacy debt obligations and capital structure. The Company has now executed a definitive agreement with a third-party investor who has acquired all outstanding notes previously held by its largest creditor, T&K Zarro, LLC. This strategic investor has expressed strong alignment with the Company's long-term vision and is committed to supporting its continued growth.

As part of the transaction, Golden Triangle Ventures and T&K Zarro, LLC have executed and closed an agreement transferring five outstanding debt instruments—representing more than $7 million in total obligations—to the new private investor. The closing was subject to several corporate actions, including an increase in the Company’s authorized share capital. In connection with the transaction, GTVH secured a fixed price repurchase right from the new investor, granting the Company the exclusive option to reacquire the full balance of the notes, at any time, for a total of $4 million. This represents a significant discount and provides a pathway to eliminate the debt under favorable terms.

FREMONT, Calif, July 01, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ: ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced that it has entered into definitive agreements for the issuance and sale of 1,626,019 shares of its common stock, Series A-3 warrants to purchase up to an aggregate of 1,626,019 shares of common stock and short-term Series A-4 warrants to purchase up to an aggregate of 3,252,038 shares of common stock, at a purchase price of $0.615 per share and associated warrants in a private placement priced at-the-market under Nasdaq rules.

Singapore , July 01, 2025 (GLOBE NEWSWIRE) -- YY Group Holding Limited (NASDAQ: YYGH) (“YY Group,” “YYGH,” or the “Company”), a global leader in on-demand workforce solutions and integrated facility management (IFM), is pleased to announce its acquisition of Pesticide Pest Control Pte. Ltd., a Singapore-based pest control company with over 30 years of operational history.

ALLIANCE DEVELOPPEMENT CAPITAL SIIC

Financing co-led by Ferring Ventures S.A. and Apeiron Investment Ltd. with participation from new and existing healthcare-focused institutional investors, including Ally Bridge Group and ADAR1